ORLANDO, FL USA (UroToday.com) - Prostate cancer biomarkers have tremendous potential to influence decisions regarding treatment and active surveillance. The CCP (cell cycle progression) score is a 46-gene expression level biomarker already known to be a robust predictor of prostate cancer outcomes. Dr. Jack Cuzick and colleagues performed validation of the CCP score and a combined clinical risk score (CCR + clinical variables) for predicting disease-specific mortality (DSM) in a cohort of conservatively managed patients diagnosed by needle biopsy. CCP score was calculated by extracting mRNA from prostate needle biopsy specimens in 757 men diagnosed with clinically localized prostate cancer. The primary endpoint was disease specific mortality, with a mean clinical follow-up of 10.6 years.

auaA change in the CCP score from the 25th to 75th percentile increased the hazard of DSM by 2.3 fold. Following multivariable analysis, CCP remained associated with an increased risk of DSM (HR 1.86). Of the variables examined, including CAPRA score and clinical parameters, CCP was the most significant independent prognostic factor for DSM. The CCR score was also predictive of DSM, while addition of CAPRA did not add significant prognostic information to the CCR score. CCP provides significant pre-treatment prognostic information for patients managed conservatively with active surveillance or watchful waiting, and is a valuable addition for the informed management of newly diagnosed PC patients.

Presented by Peter T. Scardino, MD, FACS at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Click HERE to listen to Peter Scardino, MD, FACS discuss the study.

Click HERE to view the poster from this session.

Memorial Sloan Kettering Cancer Center, New York, NY USA

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com.


Upcoming urology industry events
April 27-29, 2018 / European Society for Medical Oncology Update for Practising Oncologists
European Society for Medical Oncology Update for Practising Oncologists
May 14, 2018 / InterContinental Mark Hopkins Hotel
SITC Cancer Immune Responsiveness Workshop
May 16-17, 2018 / InterContinental Mark Hopkins Hotel
SITC Immuno-Oncology Biomarkers: State of the Art Workshop
May 17, 2018 / Moscone Convention Center North/South, San Francisco, CA
SAU 2018 Annual Meeting at the AUA
Print publications focusing on urological cancer treatments through original commentary & articles

Everyday Urology™ - Oncology Insights

From the Editor

Prostate Cancer and Prostatic Diseases

From the Editor